Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 47, n° 2PB
pages 193-195 (août 2002)
Doi : 10.1067/mjd.2002.109255
Thalidomide therapy for cicatricial pemphigoid
 

Daihung Jay Duong, MDa, Richard T. Moxley, MDa, Robert M. Kellman, MDb, Stephanie H. Pincus, MDc, Anthony A. Gaspari, MDc
From the Departments of Neurology and Otolaryngology,a State University of New York at Syracuse, Department of Dermatology, State University of New York at Buffalo,b and Departments of Dermatology and Microbiology/Immunology and the Cancer Center, University of Rochester School of Medicine and Dentistry.c 

Abstract

Cicatricial pemphigoid is a chronic, presumed autoimmune, blistering disease of the mucous membranes and occasionally of the skin. The characteristic feature is scarring at the sites of healing. We report the use of thalidomide as a therapeutic agent to control previously resistant disease. (J Am Acad Dermatol 2002;47:S193-5).

The full text of this article is available in PDF format.

 Supported by NIH grant 1R01AH/OH4108-03.


Top of the page

© 2002  The American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@